iShares Nasdaq Biotechnology ETF (IBB) Shares Bought by Mcmillion Capital Management Inc.

Mcmillion Capital Management Inc. increased its stake in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 3.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,536 shares of the financial services provider’s stock after purchasing an additional 732 shares during the quarter. Mcmillion Capital Management Inc.’s holdings in iShares Nasdaq Biotechnology ETF were worth $2,870,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Albion Financial Group UT lifted its holdings in iShares Nasdaq Biotechnology ETF by 1.1% in the second quarter. Albion Financial Group UT now owns 98,383 shares of the financial services provider’s stock worth $10,804,000 after purchasing an additional 1,104 shares during the period. Martin & Co. Inc. TN raised its position in iShares Nasdaq Biotechnology ETF by 9.6% in the second quarter. Martin & Co. Inc. TN now owns 35,863 shares of the financial services provider’s stock worth $3,938,000 after acquiring an additional 3,130 shares in the last quarter. Mader & Shannon Wealth Management Inc. bought a new stake in iShares Nasdaq Biotechnology ETF in the second quarter worth about $3,799,000. Private Capital Advisors Inc. raised its position in iShares Nasdaq Biotechnology ETF by 0.9% in the third quarter. Private Capital Advisors Inc. now owns 80,481 shares of the financial services provider’s stock worth $9,814,000 after acquiring an additional 724 shares in the last quarter. Finally, Exane Derivatives raised its position in iShares Nasdaq Biotechnology ETF by 223,000.0% in the second quarter. Exane Derivatives now owns 2,231 shares of the financial services provider’s stock worth $245,000 after acquiring an additional 2,230 shares in the last quarter. 65.86% of the stock is owned by institutional investors and hedge funds.

iShares Nasdaq Biotechnology ETF stock traded up $0.72 during midday trading on Friday, hitting $108.79. The company’s stock had a trading volume of 19,093 shares, compared to its average volume of 2,589,481. iShares Nasdaq Biotechnology ETF has a 12 month low of $100.22 and a 12 month high of $122.97.

About iShares Nasdaq Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: Yield Curve

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply